Low ANXA10 expression is associated with disease aggressiveness in bladder cancer

Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevanc...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2011-10, Vol.105 (9), p.1379-1387
Main Authors: Munksgaard, P P, Mansilla, F, Brems Eskildsen, A-S, Fristrup, N, Birkenkamp-Demtröder, K, Ulhøi, B P, Borre, M, Agerbæk, M, Hermann, G G, Ørntoft, T F, Dyrskjøt, L
Format: Article
Language:English
Subjects:
692/53/2423
692/699/67/322
692/699/67/589/1336
692/700/1750
Annexins - metabolism
Biomarkers, Tumor - analysis
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cancer Research
Disease Progression
Disease-Free Survival
Down-Regulation
Drug Resistance
Epidemiology
Female
Gene Knockdown Techniques
Humans
Male
Middle Aged
Molecular Diagnostics
Molecular Medicine
Neoplasm Invasiveness
Neoplastic Cells, Circulating
Oncology
Prognosis
Urinary Bladder Neoplasms - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Markers for outcome prediction in bladder cancer are urgently needed. We have previously identified a molecular signature for predicting progression in non-muscle-invasive bladder cancer. ANXA10 was one of the markers included in the signature and we now validated the prognostic relevance of ANXA10 at the protein level. Methods: We investigated ANXA10 expression by immunohistochemistry using a tissue microarray with 249 Ta and T1 urothelial carcinomas. The expression of ANXA10 was also investigated in an additional set of 97 more advanced tumours. The functional role of ANXA10 in cell lines was investigated by siRNA-mediated ANXA10 knockdown using wound-healing assays, proliferation assays, and ingenuity pathway analysis. Results: Low expression of ANXA10 correlated with shorter progression-free survival in patients with stage Ta and T1 tumours ( P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2011.404